Norwood Abbey is pleased to advise its subsidiary Norwood...

Norwood Abbey is pleased to advise its subsidiary Norwood Immunology Ltd [AIM:NIM], has announced the completion of the Melbourne pilot exploratory clinical study in cancer patients undergoing chemotherapy and bone marrow transplantation (BMT). The study sought to determine whether an LHRH agonist can enhance recovery of T cells, which are essential for immune defence mechanisms. Analysis of the data support the interim results as previously announced at the American Haematology Society conference in December 2003.

The results of the study are currently being fully analyzed and a journal prepared for submission to a peer reviewed journal. Analysis of the key data however, demonstrated a significant increase in naïve CD4+ T cells and CD4+ TRECs, confirming the interim results reported previously.